Page 4 - Ramesh Krishnamurthy News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Synopsis Favipiravir is one of the leading oral anti-viral treatment approved in various countries for the potential treatment of patients with mild to moderate COVID-19 disease. AFP The company said it will work closely with the various governments and medical community to ensure availability of Favulous to patients across the country. (Representative image) Drug firm Vivimed Labs on Monday said it has received approval from the Director General of Health Services (DGHS) to manufacture and market Favipiravir tablets in India, used for the treatment of mild to moderate cases of COVID-19. Viv...

HYDERABAD: Pharma player Vivimed Labs Ltd on Monday said it has received approval from the director general of health services (DGHS), government of India, to manufacture and market Favipiravir tablets of 200mg and 400mg strengths in the Indian market. The Hyderabad-based niche specialty chemicals and pharmaceuticals player said it will be marketing the oral anti-viral drug under its own brand Favulous. Favipiravir, which has been approved for treating patients with mild to moderate Covid-19 disease in several countries. Commenting on the rollout, Ramesh Krishnamurthy, CEO, Vivimed Labs Lt...

Vivimed Labs rose 3.76% to Rs 17.95 after the company announced that it received approval for two products from Uzbekistan Government.The company received approval for Bilastin tablets and Orzole combi. Both the products are manufactured at the company's Hyderabad-based facility that has been approved by PICS & Health Canada. Bilastin tablets (brand name Flustin) is a second-generation antihistamine used in treating allergic Rhino conjunctivitis and Urticaria (hives). Orzole combi (Ofloxacin + Ornidazole) is used in treating bacterial and parasitic infections. It is used to treat gastrointes...

Vivimed Labs Limited receives 2 product approvals from Uzbekistan Posted On: 2021-03-08 04:42:48 (Time Zone: Arizona, USA) Vivimed Labs Limited ("Vivimed" or the Company), a niche Specialty Chemicals and Pharmaceuticals company, announced today that it received approval for 2 products from Uzbekistan Government for its PICS & Health Canada approved site, both facilities are situated at Hyderabad PRODUCT: Bilastin tablets( Brand Name FLUSTIN)- is a second-generation antihistamine (a selective histamine Hi receptor antagonist) USES: It is used in the treatment of allergic Rhino conjunctivi...

Synopsis The company has received approval for Bilastin tablets, which are used for the treatment of allergic Rhino conjunctivitis and Urticaria, the Hyderabad-based company said in a regulatory filing. Reuters Vivimed Labs on Monday said it has received approval from the Uzbekistan government for two products. The company has received approval for Bilastin tablets, which are used for the treatment of allergic Rhino conjunctivitis and Urticaria, the Hyderabad-based company said in a regulatory filing. Vivimed has also received approval for Orzole combi, which is used to treat gastrointestinal...